Use of machine learning in prediction of granule particle size distribution and tablet tensile strength in commercial pharmaceutical manufacturing
In the manufacturing of pharmaceutical Oral Solid Dosage (OSD) forms, Particle Size Distribution (PSD) and Tensile Strength (TS) are common in-process tests that are controlled in order to achieve the quality targets of the end-product. The Quality by Design (QbD) concept elaborates process understanding and sufficient controls. However, for older pharmaceutical products upscaled to commercial phase with Quality by Testing (QbT) approach, the knowhow of the product-specific critical parameters is often limited. In this study, two predictive machine learning (ML) models were used for a commercial tablet product, for which historical data of raw materials, production, in-process controls and condition monitoring were available.
- • Data of generic commercial pharmaceutical product was utilized with novel approach.
- • Machine learning models were used to predict PSD and tablet tensile strength.
- • Feature importances were evaluated to identify product relevant variables.
- • Machine learning was used to elaborate knowledge of the manufacturing process.
With the aforementioned data, the aim was to predict the PSD and the TS that indicate the product quality. The feature importance was used to evaluate the parameter importance for the PSD and the TS. Partial dependence, in turn, was used to estimate the parameter impact on the predicted TS. The study illustrates the capability of the ML models to bring additional value for commercial products through the enhanced product-related knowhow.
See the article here
Eero Mäki-Lohiluoma, Niko Säkkinen, Matti Palomäki, Oscar Winberg, Hung Xuan Ta, Timo Heikkinen, Eero Kiljunen, Ari Kauppinen,Use of machine learning in prediction of granule particle size distribution and tablet tensile strength in commercial pharmaceutical manufacturing, International Journal of Pharmaceutics, Volume 609, 2021, 121146, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2021.121146.